Skip to main content
. 2026 Feb 12;27(4):1774. doi: 10.3390/ijms27041774
AHT Anti-hormone therapy
BCL2i BCL-2 inhibitors
CDK46i Cyclin-dependent kinase 4/6 inhibitors
CDX Cell-derived mice xenograft
CI Combination index
FAKi Focal adhesion kinase inhibitors
GR Growth rate
HGSOC High-grade serous ovarian cancer
IHC Immunohistochemistry
LGSOC Low-grade serous ovarian cancer
MAPK Mitogen-activated protein kinase
MEKi MEK inhibitors
OS Overall survival
PFS Progression-free survival
PLB Palbociclib
Rb Retinoblastoma
RECIST Response Evaluation Criteria in Solid Tumors
RR Response rates
SD Standard deviation
SEM Standard error of the mean
TMA Tissue microarray
TRA Trametinib
TRA_R TRA-resistant
TRA_SR TRA-super resistant
WB Western blot